Myotoxicity of Lipid-Lowering Agents in a Teenager With MELAS Mutation

Tay, Stacey K.H.; DiMauro, Salvatore; Pang, Aileen Yu-Wen; Lai, Poh-San; Yap, Hui-Kim

doi:10.1016/j.pediatrneurol.2008.09.002

Cited by 29 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In many mitochondrial cytopathies, there is respiratory chain function impairment, and statin-induced lowering of CoQ might in theory exacerbate the underlying disorder. Two rather limited case reports of patients with the mtDNA A3243G mutation suggested that statins might have precipitated features of MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes) syndrome in one36 and elevated serum CK in the other 37. I am aware of verbal anecdotal reports of statins apparently exacerbating fatigue and weakness in other mitochondrial disorders, but once again the nocebo effect needs to be considered, and there is a complete lack of literature to suggest that this is a major issue.…”

Section: Statins In Those With Pre-existing Myopathymentioning

confidence: 99%

Statin-related myopathies

Hilton‐Jones

2018

Pract Neurol

View full text Add to dashboard Cite

Statins are the Marmite ('You either love it or hate it!') of the drug world, both in terms of therapeutic benefit and risk of side effects. Proponents think that they are potential life-savers, opponents that their main benefit is lining the pockets of pharma. Some consider side effects to be a major issue, outweighing any therapeutic benefit, others that they are rare and essentially innocuous. Statin-induced myalgia is relatively common but often mild and for most people does not limit treatment. In others, reducing the dose or changing the preparation may help. In all, withdrawal of the statin leads to resolution. Statin-induced rhabdomyolysis, most often precipitated by drug-drug interaction, affects only a tiny proportion of statin users, but because of the widespread prescribing of statins is an important clinical problem. Statin-induced immune-mediated necrotising myopathy represents a novel disease mechanism and clinically mimics forms of myositis. Resolution often requires immunosuppressant drug treatment, as well as statin withdrawal.

show abstract

Section: Statins In Those With Pre-existing Myopathymentioning

confidence: 99%

Statin-related myopathies

Hilton‐Jones

2018

Pract Neurol

View full text Add to dashboard Cite

show abstract

“…Statins can uncover clinically silent musculoskeletal conditions such as autoimmune muscle disease (often previously subclinical polymyalgia rheumatica) or primary muscle disease, including McArdle's disease, acid maltase deficiency, myoadenylate deaminase deficiency, muscular dystrophies [45], and even mitochondrial encephalopathy [46]. All of these can be the reason for persistent myopathy poststatin withdrawal [13,45].…”

Section: Primary Muscle Diseasementioning

confidence: 99%

Statin myopathy

Maghsoodi

Wierzbicki²

2016

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

“…34 Statins should also be avoided, if possible, because they may precipitate or exacerbate myopathy in MELAS mutation carriers. 35,36 Moyamoya Disease Moyamoya disease is associated with recurrent TIA, ischemic stroke, and hemorrhagic stroke. In children with moyamoya disease, ischemic stroke and TIA are more prevalent and may be triggered by exercise, crying, coughing, fever, or hyperventilation; in adults, intraparenchymal and intraventricular hemorrhage is more prevalent.…”

Section: Retinal Vasculopathy With Cerebral Leukodystrophymentioning

confidence: 99%